Mounjaro (tirzepatide) first GIP and GLP-1 receptor agonist approved for type 2 Diabetes Pen Injector
What is Mounjaro?
Mounjaro is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. It is not known if Mounjaro can be used in people who have had inflammation of the pancreas (pancreatitis). Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age.
Great Savings
(469) 625-1000 | info@medrocs.com
Mounjaro (tirzepatide) injection is now available at Medrocs Pharmacy.
How to use Mounjaro?
Mounjaro is an injectable medication used as Once-Weekly injection, comes in a single dose Pen.
Read the Instructions for Use included with your pen.
How to Use Mounjaro, video instructions
How to store Mounjaro pens?
- Keep Mounjaro in the refrigerator
- Make sure the temperature is between 36°F to 46°F (2°C to 8°C)
- Store the pens in the original packaging to protect your pen from light
- Do not freeze the Mounjaro pens
- The pen has glass parts. Handle it carefully.
- If you drop the Pen on a hard surface, do not use it. Use a new pen for your injection
How long Mounjaro can be kept outside refrigerator?
- Mounjaro can last unrefrigerated for up to 21 days.
- Just make sure the temperature does not get any higher than 86°F (30°C).
- Keep your pen in its original carton to protect your pen from light.
Mounjaro Dosing
Mounjaro Pen is available in Multiple Dosages.
Start - 2.5mg
Continue - 5mg
Additional Dose Increases
Let your doctor know how you’re doing on the 2.5-mg and 5-mg doses during your checkup. Once you reach 5 mg, your doctor may keep you at the same dose for longer than 4 weeks. You’ll work together to decide if your dose needs to be increased beyond 5 mg.
7.5mg
10mg
12.5mg
15mg
Pediatric Use
Safety and effectiveness of Mounjaro have not been established and use is not recommended in patients less than 18 years of age.
FDA Approval link
FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes